85 results about "Abdominal aneurysm" patented technology

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The invention belongs to the field of biological medicine, particularly discloses application of glycyrrhetinic acid or glycyrrhetinic acid lipidosome in preparation of an abdominal aortic aneurysm protection medicine, and reveals that glycyrrhetinic acid can effectively improve death of mice after aorta rupture caused by Ang II treatment, can obviously improve degradation of an aorta elastic fiber layer caused by Ang II treatment, and can improve the aortic aneurysm protection effect. The macrophages induced by lipopolysaccharide (LPS) can be promoted to be polarized to M2 type; the glycyrrhetinic acid is used for intervention before Ang II treatment, the occurrence of Ang II induced abdominal aortic aneurysm can be relieved, the survival rate of mice is increased, and it is indicated that the glycyrrhetinic acid can be used for preparing the medicine for relieving the abdominal aortic aneurysm. Furthermore, the glycyrrhetinic acid is entrapped into the liposome, so that the solubility and bioavailability of the glycyrrhetinic acid are improved, meanwhile, after glycyrrhetinic acid coating is carried out by utilizing a nanotechnology, the dosage of the glycyrrhetinic acid can be effectively controlled, and the curative effect of the glycyrrhetinic acid is further improved and enhanced.

The invention discloses an abdominal aortic aneurysm risk screening method based on HbA1c multiple risk markers, and aims to solve the problems that AAA screening in the prior art depends on a single marker, is lack of nonlinear analysis and is insufficient in application tool, a comprehensive risk prediction model is constructed by integrating HbA1c, proteomics data and non-genetic factors, a nonlinear risk relationship is revealed, and the risk of the abdominal aortic aneurysm is predicted to be the risk of the abdominal aortic aneurysm of the abdominal aortic aneurysm of the abdominal aortic aneurysm. And an application tool is developed, visual display of the morbidity probability and the risk level of n years is provided, a personalized screening strategy is supported, and the accuracy and practicability of AAA early screening are improved.

The invention discloses a screening method of a protein marker combination, which is used for risk prediction of abdominal aortic aneurysm or ruptured abdominal aortic aneurysm, and optimizes the stability of a protein expression profile by constructing an initial protein expression profile; screening differential expression proteins by adopting statistical analysis, and preliminarily locking candidate proteins remarkably associated with a disease endpoint based on survival analysis or a risk regression model; performing cross validation by combining a sparse constraint algorithm and a nonlinear feature selection algorithm, and extracting a robust core marker; the independent contribution degree of each marker is evaluated through the standardized weight, and finally the optimal protein combination for disease prediction or diagnosis is determined. According to the method, six core proteins obtained through multi-algorithm cross screening can be detected in serum, multivariable logistic regression and external verification set performance both show good robustness, and an aorta protein fingerprint feature set which can be popularized and explained is formed.

The invention belongs to the technical field of biology, and particularly relates to an immunogenic peptide fragment aiming at a human sphingosine 1-phosphate receptor 2 and application of the immunogenic peptide fragment. The amino acid sequence of the immunogenic peptide fragment is SEQ ID No.1. The immunogenic vector vaccine aiming at the human sphingosine 1-phosphate receptor 2 is prepared by coupling the immunogenic peptide fragment of the human sphingosine 1-phosphate receptor 2 and a vector, and the vector is Q beta-2aa bacteriophage virus-like particle protein. According to the invention, the preferentially designed immunogenic peptide fragment of the human sphingosine 1-phosphate receptor 2 is coupled with the Qbeta-2aa bacteriophage virus-like particle protein carrier to successfully prepare the carrier vaccine. The immunogenic vector vaccine can be used for preparing drugs for preventing and treating abdominal aortic aneurysm.

The invention discloses shRNA (short hairpin Ribonucleic Acid) for targeted knockout of an Eif2ak2 gene and application, and belongs to the technical field of gene engineering. The shRNA comprises a positive-sense strand and an antisense strand which is reversely complementary with the positive-sense strand, and the nucleotide sequence of the positive-sense strand is shown as SEQ ID NO. 5. It is found for the first time that the recombinant adeno-associated virus capable of inhibiting Eif2ak2 gene expression can successfully inhibit the phenotype of the abdominal aortic aneurysm of a mouse, obviously reduce the morbidity of the abdominal aortic aneurysm of the mouse, improve the severity of the abdominal aortic aneurysm of the mouse, reduce the inner diameter of a blood vessel and the ratio of the weight to the body weight of the blood vessel, and promote the contraction function of vascular smooth muscle cells of the mouse; the method can be used for effectively treating the abdominal aortic aneurysm, provides a new thought and strategy for treating the abdominal aortic aneurysm, and has a wide clinical application prospect.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The invention belongs to the technical field of biology, and particularly relates to a tremella aurantialba methanol extract and a preparation method and application thereof.The preparation method comprises the following steps that S1, pretreatment is conducted, specifically, a prepared tremella aurantialba raw material is freeze-dried, and the dried raw material is ground; s2, extraction: adding an extraction solvent methanol-water solution, and performing magnetic stirring for extraction; s3, post-treatment: after the extraction is completed, combining the extracting solutions, filtering, performing vacuum concentration to obtain paste, and performing vacuum freeze-drying on the obtained paste to obtain the tremella aurantialba methanol extract. The tremella aurantialba methanol extract can obviously relieve the occurrence and progress of Ang II induced aneurysm, not only provides a new medicine for preventing and treating abdominal aortic aneurysm, but also provides a new thought for development and utilization of tremella aurantialba resources.

Devices, systems, and method for treating abdominal aortic aneurysms are disclosed. An illustrative system can include an occlusion catheter with an elongate catheter shaft. The elongate catheter shaft can have a first expandable member and a second expandable member. The elongate catheter shaft can have a therapeutic fluid infusion port disposed in an isolated area between the first expandable member and the second expandable member, where the occlusion catheter is configured to infuse a therapeutic fluid via the elongate catheter shaft and through the therapeutic fluid infusion port to a position proximate to an abdominal aortic aneurysm in the isolated area. The illustrative system including an elongate light-emitting catheter including a light-emitting element, wherein the light-emitting element is configured to emit light and be disposed at the position.

The application belongs to the technical field of biological medicine, and relates to application of a CXCL14 inhibitor in preparation of a drug for preventing or treating abdominal aortic aneurysm of a patient. The inhibitor effectively eliminates the gender difference of abdominal aortic aneurysm by specifically blocking the combination of CXCL14 and its receptor CXCR4, significantly reduces aortic macrophage infiltration and PDGFRA + macrophage accumulation in the progress of abdominal aortic aneurysm, reduces the degree of collagen degradation and elastic fiber damage, and thus inhibits the pathological progress of abdominal aortic aneurysm. The application provides a new target and drug combination for precise treatment of male abdominal aortic aneurysm, and has clear clinical application value.

A system and a method for continuously monitoring an abdominal aortic aneurysm are described. The system (100) comprises an internal unit (10), which comprises at least one sensor (S1, S2, S3, S4) for detecting blood pressure and flow data inside the aneurysmal sac and an electronic control unit (11) in electrical communication with the at least one sensor (S1, S2, S3, S4); an external unit (20) in electrical communication with the internal unit (10); and a remote server (30) in electrical communication with the external unit (20). The external unit (20) is configured to read the blood pressure and flow data detected by the at least one sensor (S1, S2, S3, S4) of the internal unit (10) and transmit them to the remote server (30) for their analysis, organization and protection.

1. Name of the product in this design: Packaging box for early risk warning kit for abdominal aortic aneurysm. 2. Purpose of this design: For the outer packaging of an early risk warning kit for abdominal aortic aneurysm. 3. The key design feature of this product is its pattern. 4. The image or photograph that best illustrates the design's key features: the front view.

The invention relates to the technical field of biological medicines, and particularly relates to a method for researching the influence of silencing or inhibiting a UBE2G1 gene on the growth of abdominal aortic aneurysm by constructing a UBE2G1 gene function deletion mouse model. Results show that silence or inhibition of UBE2G1 gene expression can inhibit growth of abdominal aortic aneurysm, alleviate destruction of elastic fibers of arterial tissues, reduce levels of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in a body and inhibit polarization of macrophage M1. According to the invention, a certain theoretical basis is provided in the aspect of treatment of abdominal aortic aneurysm by means of biotechnology, and the UBE2G1 gene (or protein) can be used as a drug target for treatment of abdominal aortic aneurysm.

The present invention belongs to the field of biomedicine and specifically discloses the use of glycyrrhetinic acid or glycyrrhetinic acid liposomes in the preparation of a drug for protecting against abdominal aortic aneurysms. It reveals that glycyrrhetinic acid can effectively ameliorate the mortality of mice following aortic rupture caused by Ang II treatment, significantly improve the degradation of the aortic elastic fiber layer caused by Ang II treatment, and promote the polarization of lipopolysaccharide (LPS)-induced macrophages toward the M2 type. Intervention with glycyrrhetinic acid before Ang II treatment can alleviate the occurrence of Ang II-induced abdominal aortic aneurysms and improve the survival rate of mice, indicating that glycyrrhetinic acid can be used to prepare a drug for alleviating abdominal aortic aneurysms. Furthermore, the present invention improves the solubility and bioavailability of glycyrrhetinic acid by encapsulating it in liposomes. At the same time, after glycyrrhetinic acid is encapsulated using nanotechnology, its dosage can be effectively controlled, further improving and enhancing the therapeutic effect of glycyrrhetinic acid.

The invention discloses an abdominal aortic aneurysm serum protein fingerprint detection and analysis method and system based on an LASSO regression algorithm. The method comprises the following steps: by optimizing a serum sample pretreatment process and combining an MALDI-TOFMS (Matrix-Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry) mass spectrometry technology and high-throughput proteomics data analysis, screening differentially expressed proteins related to occurrence, development and rupture of abdominal aortic aneurysm in serum; and further constructing a risk assessment model based on the key protein combination by using an LASSO machine learning algorithm. The method provided by the invention has the advantages of high sensitivity and good specificity, can effectively distinguish abdominal aortic aneurysm patients from normal people, can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, and provides important tools and bases for clinical early diagnosis, risk stratification and personalized treatment decision.

The invention relates to the technical field of animal model construction, and discloses a mouse abdominal aortic aneurysm model construction method. The construction method comprises the step that in a 18-month-old mouse, a sterile cotton piece soaked with elastinase is used for wrapping the kidney subabdominal aorta to induce formation of the abdominal aortic aneurysm. The mouse model can better reflect the degenerative change of the aortic wall of an elderly patient, better fits the clinical manifestation in the development speed and severity of aortic aneurysm, can more stably simulate the development process of the abdominal aortic aneurysm of the elderly patient, can be used as an effective tool for studying senescence-related aneurysm diseases, and has a wide application prospect. The method is helpful for revealing acceleration and aggravation processes of the elderly individuals in pathological development, and provides a more targeted theoretical basis and experimental support for designing and evaluating a new treatment method.

The invention provides a biomarker combination for evaluating the progress of abdominal aortic aneurysm based on an adventitia and application of the biomarker combination, and the biomarker combination comprises at least two biomarkers selected from the following three independent groups, the at least two markers are from the same group or different groups: a myofibroblast transformation marker group: alpha-smooth muscle actin, monocyte chemotactic protein 1 and a tissue metalloproteinase inhibitor 1; the lipid metabolism related biomarker group comprises a lipid metabolism related protein CD36, carnitine palmitoyl transferase 1 and a fatty acid binding protein 4; and an inflammatory factor related biomarker group: IL-6, MCP-1 and TIMP1. According to the biological marker combination for evaluating the progress of the abdominal aortic aneurysm based on the adventitia, multi-channel biological markers are systematically integrated, an innovative tool is provided for accurate diagnosis, drug screening and curative effect monitoring of AAA, and meanwhile, an important foundation is laid for developing a collaborative treatment strategy based on adventitia fibroblast regulation.

The application discloses a method for separating and culturing primary vascular smooth muscle cells from human abdominal aortic wall, and relates to the technical field of human cell culture. The method comprises the following steps: obtaining a collagenase A solution; adding the collagenase A solution to a treated human abdominal aortic aneurysm wall tissue sample and then cutting the sample; transferring the cut human abdominal aortic aneurysm wall tissue sample to a 37-degree cell culture box for culture; centrifuging a cell suspension obtained after termination of digestion; discarding supernatant, resuspending cell precipitate, and repeating centrifugation for three times; resuspending the cell precipitate again, uniformly transferring the cell precipitate to a T25 culture bottle after blowing, and placing the cell precipitate in a 37-degree cell culture box for culture; when a wave peak and wave trough state appears, the cell precipitate is digested and subcultured by using 0.25% trypsin, and then the cell precipitate is transferred to a new T25 culture bottle; and the cell precipitate is subcultured normally to the P3 generation and then stored in liquid nitrogen, so that the cell damage is prevented and the activity and proliferation capacity of the cell are maintained.

The invention provides an abdominal aortic aneurysm early prediction model construction method, system and device and a medium. According to the method, a balanced research queue is constructed through fusion of multi-modal data (ultrasonic images, biochemical indexes and lipidomics) and tendency score matching, so that the accuracy of early risk identification of the abdominal aortic aneurysm and the model robustness are remarkably improved; furthermore, on the basis of a risk migration strategy, the discrimination capability of the complex deep learning model is migrated to a simplified logistic regression model which only needs a simplest lipid feature set and basic demographic information, so that high prediction performance is maintained, model lightweight, parameter immobilization and clinical interpretability are realized, the detection cost and the operation complexity are greatly reduced, and the detection efficiency is improved. A high-precision risk prediction technology can be conveniently deployed in a basic medical scene, and finally an abdominal aortic aneurysm early screening solution with high precision, high interpretability and wide applicability is formed.

The application belongs to the technical field of molecular diagnosis, and particularly relates to a group of extracellular vesicle proteins as biomarkers for diagnosing abdominal aortic aneurysm and application. The application early diagnoses abdominal aortic aneurysm through determination of circulating extracellular vesicle protein markers, and provides an effective tool for diagnosis of abdominal aortic aneurysm. The extracellular vesicle protein marker is any one or two or more molecular marker combinations of interleukin-4 (IL-4), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (Neurturin) and tumor suppressor M (Oncostatin-M). The application uses proteins in extracellular vesicles as specific markers for early diagnosis of abdominal aortic aneurysm, which is a less applied field in current early diagnosis of AAA. The specific proteins in EVs may be directly related to the pathological process of AAA, and are different from conventional serum markers, and have higher specificity and sensitivity.

The invention relates to an abdominal aortic aneurysm filling system and treatment system, the filling system comprises a filling assembly, the filling assembly comprises at least two filling blocks, each filling block adopts shape memory polymer foam, and each filling block has a compressed loading state and an implantation state of expanding at a preset position; the interventional catheter is used for containing the filling assembly to implement interventional delivery, and the filling blocks are sequentially arranged in the extending direction of the interventional catheter in the loading state; the connecting shaft is arranged in the interventional catheter in a sliding mode, the far-end portion of the connecting shaft sequentially penetrates through and is connected with the filling blocks so as to carry the filling blocks to be released from the far-end side of the interventional catheter into the abdominal aortic aneurysm, and the far-end portion of the connecting shaft is configured to be spirally wound around a space axis in a pre-shaping mode. The surgical operation process is simplified, the filling blocks are arranged relatively orderly after being released and expanded, the space filling rate is high, and the surgical treatment effect is further improved.

The invention belongs to the technical field of medicines, and particularly relates to a prodrug for supplementing NAD < + >, which is an NAMPT agonist YB8, and an application of the prodrug in prevention and treatment of abdominal aortic aneurysm. The invention discloses a prodrug YB8 capable of specifically activating nicotinamide phosphoribosyltransferase (NAMPT), and the prodrug YB8 can effectively improve the level of NAD + (nicotinamide adenine dinucleotide) in cells, so that the degenerative change of a vascular structure is slowed down, the purposes of protecting blood vessels and treating abdominal aortic aneurysm are achieved, and the YB8 is proved to be used as a specific activator of NAMPT for the first time. The multi-target treatment effect is achieved by improving the blood vessel NAD + level; the discovery provides a brand new strategy for the drug treatment of abdominal aortic aneurysm, and the treatment advantages are as follows: ultrasonic imaging proves that the tumor progress can be obviously inhibited; the discovery lays an important foundation for developing clinical treatment of abdominal aortic aneurysm based on NAD + metabolism regulation.

The invention discloses application of a biomarker in preparation of a product for diagnosing abdominal aortic aneurysm, a kit and a use method, the biomarker has the advantages of high sensitivity, strong specificity and high accuracy, and the detection method is simple and rapid and has important significance in early screening of abdominal aortic aneurysm. The biomarker is any one of the following exosome proteins or a combination thereof: fibrinogen beta chain, fibronectin, lysosome related membrane glycoprotein 2 and histone H4.

The invention relates to application of a JAML gene in preparation of an abdominal aortic aneurysm resisting medicine, and belongs to the technical field of biological medicine. The nucleotide sequence of the JAML gene is as shown in SEQ ID No.1. The application of the JAML gene in preparation of the abdominal aortic aneurysm resisting medicine comprises the following two aspects: (1) applying the JAML gene as an action target to preparation of the abdominal aortic aneurysm resisting medicine; and (2) applying the JAML gene as an action target to screening of drugs for resisting abdominal aortic aneurysm. According to the invention, a gene knockout mouse of which the smooth muscle specifically knockout JAML is constructed, and then the mouse abdominal aortic aneurysm model is constructed by subcutaneously pumping AngII, so that the morbidity of abdominal aortic aneurysm can be obviously reduced after the JAML gene is knocked out; therefore, a theoretical basis is provided for preparing or screening drugs or preparations for inhibiting smooth muscle cell JAML gene expression as alternative drugs or preparations for resisting abdominal aortic aneurysm.

A device of this application can include (i) an improved stent graft device having a collapsible conduit to provide sealable access to an aneurysmal sac during deployment or (ii) a multiport embolization sheath configured to be used conjunction with a stent graft device.

The invention relates to the technical field of image processing, in particular to an abdominal aortic aneurysm intracavitary isolation postoperative internal leakage diagnosis system based on an ultrasound contrast image.According to the method, ultrasound images of different parameters are collected at the same position, firstly, a first ultrasound image is adopted at the high working frequency, and a second ultrasound image is adopted at the high working frequency; then, a second ultrasonic image is collected at low working frequency; the first ultrasonic image and the second ultrasonic image are preprocessed through different preprocessing methods, then the first ultrasonic image is input into an artificial intelligence model to be used for determining the position of the aortic aneurysm, and then the position of the aortic aneurysm in the second ultrasonic image is obtained according to the position; and then inputting the aortic aneurysm in the second image into the artificial intelligence model, thereby realizing internal leakage diagnosis. By means of the mode, the situation that in the prior art, two kinds of ultrasonic images are subjected to image fusion through a complex algorithm and then diagnosis is conducted is avoided, the process is simple, and the diagnosis efficiency is improved.

The invention relates to the technical field of medical instruments, in particular to an abdominal aortic aneurysm cavity support auxiliary positioning device. An inner tube and a positioning assembly are coaxially arranged in the outer sheath tube in a sleeving manner; the outer sheath tube is connected with the near end of the inner tube, so that the relative positions of the outer sheath tube and the inner tube can be kept consistent; the positioning assembly is arranged on the periphery of the inner tube in a sleeving mode and can slide between the outer sheath tube and the inner tube. A penetrating through hole is formed in the center of the inner tube, and a guide wire can penetrate through the penetrating through hole and slide in the inner tube. The auxiliary positioning device for the abdominal aortic aneurysm cavity support is simple in structure, easy and convenient to operate and capable of effectively assisting in positioning a main body support short iliac branch opening in an abdominal aortic aneurysm cavity, the butt joint efficiency of the main body support short iliac branch and an iliac branch extension support is improved, the operation time is shortened, the operation risk is reduced, and ray damage is reduced.

An implantable detection device (100) for continuously monitoring an abdominal aortic aneurysm is described. The device comprises a printed circuit board (10), at least one sensor (S1, S2, S3, S4) for measuring blood pressure and flow within the abdominal aortic aneurysm and electrically connected to the printed circuit board (10), and an electronic control unit (12) positioned on the printed circuit board (10) and in electrical communication with the at least one sensor (S1, S2, S3, S4). The printed circuit board (10) is flexible, so that it can be folded reversibly, during implantation of the implantable detection device.

The invention belongs to the technical field of medicine, and particularly relates to application of fructus hippophae oil in treating or preventing abdominal aortic aneurys.The application includes the steps that an AAA model is established by subcutaneously infusing Ang II through a slow release pump to induce Ldlr- / -mice, SBPO gavage intervention is carried out, and by observing the thoracico-abdominal aorta form of the mice, calculating the survival rate of the mice, calculating the AAA occurrence rate and measuring and counting the maximum diameter of the aorta of the mice, the AAA model is established; it is proved that SBPO can effectively inhibit occurrence and development of mouse abdominal aortic aneurysm, a feasible scheme is provided for treatment of abdominal aortic aneurysm diseases, and the SBPO has wide application prospects in prevention and treatment of occurrence and development of abdominal aortic aneurysm.

The invention relates to the technical field of biology, in particular to an immunogenic monoclonal antibody for treating abdominal aortic aneurysm as well as a preparation method and application of the immunogenic monoclonal antibody, and the immunogenic monoclonal antibody is a monoclonal antibody obtained by taking an immunogenic peptide fragment specifically acting on a human sphingosine 1 phosphate receptor 2 as an immunogen; wherein the amino acid sequence of the immunogenic peptide fragment is shown as SEQ.ID.NO: 1, the immunogenic monoclonal antibody can be used for preparing an injection preparation for treating abdominal aortic aneurysm, the injection preparation has the advantages of high specificity, lasting effect, good compliance and the like, the defects that JTE-013 is not high in specificity and needs to be administrated for multiple times are overcome, and the immunogenic monoclonal antibody can be used for preparing an injection preparation for treating abdominal aortic aneurysm. And a new thought is provided for treatment of AAA and related vascular diseases.